Literature DB >> 7901368

Stereoselective interaction of mianserin with 5-HT3 receptors.

M D Wood1, D R Thomas, C J Watkins, N R Newberry.   

Abstract

The interaction of the enantiomers of mianserin with the 5-HT3 receptor was determined. Using [3H]granisetron binding, (-)-mianserin was more potent than (+)-mianserin (pKi 8.46 and 6.95, respectively). The enantiomers competitively antagonized the depolarizing effect of 5-hydroxytryptamine in the rat vagus nerve preparation (pKapp: (-)-mianserin 8.13, (+)-mianserin 6.58). This stereoselectivity was maintained in-vivo as determined using ex-vivo inhibition of [3H]granisetron binding. Therefore, in contrast to its enantiomeric selectivity for the 5-HT1C and 5-HT2 receptors, where the (+)-isomer is more potent, the enantiomeric selectivity of mianserin for the 5-HT3 receptor was reversed. This differential selectivity of the enantiomers of mianserin may be useful in elucidating its utility in anxiety states.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901368     DOI: 10.1111/j.2042-7158.1993.tb07094.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

1.  Multiple 5-HT receptors in the guinea-pig superior cervical ganglion.

Authors:  C J Watkins; N R Newberry
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

Review 2.  Chirality and drugs used in psychiatry: nice to know or need to know?

Authors:  R M Lane; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 3.  Escitalopram versus citalopram: the surprising role of the R-enantiomer.

Authors:  Connie Sánchez; Klaus P Bøgesø; Bjarke Ebert; Elin Heldbo Reines; Claus Braestrup
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

Review 4.  Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects.

Authors:  Yukihiro Ohno; Naofumi Kunisawa; Saki Shimizu
Journal:  Front Pharmacol       Date:  2019-09-17       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.